The safety and antibody response of the nasal COV2 vaccine against the SARS-CoV-2 virus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509725-49-00

Acronym

COV2FIN11

Enrollment

Registered

2024-11-06

Start date

2025-01-27

Completion date

2025-08-06

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Booster immunisation against COVID-19 disease caused by SARS-CoV-2 virus

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026